JAPAN-CORN-STARCH
17.2.2017 01:54:37 CET | Business Wire | Press release
Japan Corn Starch Co., Ltd. (Minato-ku, Tokyo; Soichiro Kurachi, president. Hereby, “Japan Corn Starch” or “the company”), the largest corn wet miller in Japan has been pursuing excellent flavor in the increasingly diverse food industry, and conducting research to find the perfect balance of fructose and glucose in high-fructose corn syrup (HFCS), used in a variety of soft drinks. The company successfully developed and obtained patent for a new product, “HFCS 70” that maintains the body equal to fructose glucose liquid sugar used in many soft drinks while having the sharp sweetness of fructose, and is about to release the product.
Since its development 50 years ago, there were only three varieties of HFCS until this year, glucose-fructose liquid sugar, fructose-glucose liquid sugar, and high-fructose liquid sugar, commoditization of which made their differentiation difficult. However, by introducing HFCS 70 into the market, the company expects to overturn the stereotypes in the HFCS industry and create a new wind in the industry.
Japan Corn Starch’s new product, HFCS 70 maintains the body while realizing a high level of sharp sweetness. This allows the product to create a flavor different from fructose glucose liquid sugar, high fructose liquid sugar, or crystalline fructose that are mainstream in the soft drink industry, and help the development of delicious drinks with a new type of sweetness. In addition, because HFCS maintains the body while realizing a high level of sharp sweetness, it can be used in products such as highly refreshing and filling jellies.
Japan Corn Starch has obtained licenses such as the first FSSC22000 and HACCP in the industry and ISO22301, which is the international standard for business continuity management system (BCMS). Furthermore, the company has been making efforts such as radiation dose measurement of each product using high-performance equipment, and quantification of odor using odor identification devices. Thus the company is fully equipped for stable distribution of products.
As a comprehensive producer of starch-related products, Japan Corn Starch will continue its commitment to offer reliable, safe, and high quality products that cater our clients’ every need through its thoroughgoing distribution system.
About the Company
Company name: Japan Corn Starch Co., Ltd.
President: Soichiro
Kurachi
Head office: Akasaka Inter City 3F, 1-11-44 Akasaka, Minato
Ward, Tokyo, 107-0052
Tel: +81-3-5570-7000 (operator)
Fax:
+81-3-5570-7001
Mail: corn@japan-cornstarch.com
URL:
http://www.nihon-cornstarch.com/english
Founded:
1867
View source version on businesswire.com: http://www.businesswire.com/news/home/20170216006427/en/
Contact:
Japan Corn Starch Co., Ltd.
Kazuki Hashimoto, +81-566-42-3129
Public
Relations
corn@japan-cornstarch.com
http://www.nihon-cornstarch.com/english
fax:
+81-3-5570-7001
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Philip Morris International Announces U.S. FDA Reauthorization of IQOS as a Modified Risk Tobacco Product17.4.2026 23:43:00 CEST | Press release
A pioneer in smoke-free tobacco products, Philip Morris International is the only company that has received modified risk tobacco product authorizations for heated tobacco products.In their order, FDA concluded that: “Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces your body’s exposure to harmful or potentially harmful chemicals” The U.S. Food and Drug Administration (FDA) announced that it has authorized the renewal of modified risk tobacco product (MRTP) orders previously granted to PMI for two versions of the IQOS device and three variants of the tobacco consumables, commercialized under the HEETS brand. This renewal allows PMI to continue sharing reduced-exposure information with U.S. adults 21+ who use traditional tobacco products, such as combustible cigarettes. The agency concluded that renewing the IQOS and HEETS MRTP authorizations is appropriate to promote public health and is expected to benefit th
Canva Announces Anthropic Collaboration to Bring AI-Powered Design to Millions17.4.2026 17:51:00 CEST | Press release
New collaboration brings Canva into Claude Design by Anthropic, turning AI-generated ideas into fully editable, on-brand designs Canva, the world’s leading all-in-one visual communication platform, today announced the next chapter in its two-year strategic collaboration with Anthropic, bringing Canva directly into the newly launched Claude Design by Anthropic Labs, one day after unveiling Canva AI 2.0 to a crowd of 6,500 people at Canva Create in Los Angeles.. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260410843169/en/ Canva and Claude Canva is also today introducing HTML importing, a new capability that makes it easy to bring interactive content generated in tools like Claude into the Canva editor for drag-and-drop collaboration, refinement, and publishing. The collaboration makes it easier for Claude Design users to turn AI-generated drafts and ideas into fully editable designs in Canva, where they become collaborative
Andersen Consulting tilføjer samarbejdsfirmaet Nuvolar17.4.2026 15:43:00 CEST | Pressemeddelelse
Andersen Consulting udvider sin platform for digitale transformation gennem en samarbejdsaftale med Nuvolar, et teknologikonsulenthus med speciale i cloudbaseret softwareudvikling og avancerede Salesforce-implementeringer. Nuvolar, der blev stiftet i 2008 og har hovedsæde i Spanien, leverer end-to-end digital produktudvikling med dyb ekspertise inden for Salesforce, specialudviklede web- og mobilapplikationer, full-stack udvikling, UX/UI-design, produktledelse og langsigtede supporttjenester. Med mere end 110 fagfolk fordelt over Barcelona, Madrid, Miami og Mexico City arbejder virksomheden med kunder inden for luftfart, sundhedsvæsen, forbrugsgoder, medicinalindustrien samt hotel- og restaurationsbranchen for at designe og implementere skalerbare, forretningskritiske platforme, der optimerer driften og fremskynder den digitale transformation. "Samarbejdet med Andersen Consulting giver os mulighed for at levere vores ekspertise i en større skala," udtalte Marc Vivas, administrerende di
Qualcomm Announces Quarterly Cash Dividend17.4.2026 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.92 per common share, payable on June 25, 2026, to stockholders of record at the close of business on June 4, 2026. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing business
Byondis to Present Data from its Novel ADC Technology Platforms at the American Society for Cancer Research Meeting 202617.4.2026 13:00:00 CEST | Press release
Byondis B.V., an independent biopharmaceutical company creating innovative targeted medicines for patients with cancer, will profile the Company’s first-in-class antifolate and phosphonate antibody-drug conjugate (ADC) technology platforms in poster sessions at the American Society for Cancer Research (AACR) Annual Meeting 2026 in San Diego, CA, from today through to 22 April. Wim Dokter, PhD, Chief Scientific Officer at Byondis, said: “The research we are presenting at AACR highlights the potential of two of our state-of-the-art ADC technology platforms to address significant limitations with current therapeutic approaches in cancer treatment. Our first-in-class antifolate linker-drug platform features an orthogonal mechanism of action based on clinically validated biology. This approach is engineered to address acquired resistance that can develop with current ADC treatments, positioning it for use across treatment lines. Our phosphonate linker-drug platform offers a complementary me
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom